ERBB2 and breast cancer: In a recent meeting held in Milan for discussing scientific and organizational issues related to multigene testing in Italian pathology units, including reimbursement for IHC characterization and proper funding of the additional workload, we propose that pathologists could order a multigene test for female ER + /HER2- early BC patients, aged <65 years and matching the following criteria: